{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["diabetes", "metabolic syndrome", "nanoformulation", "natural products"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "31406461", "DateCompleted": {"Year": "2019", "Month": "10", "Day": "18"}, "DateRevised": {"Year": "2024", "Month": "07", "Day": "18"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "07", "Day": "16"}], "Language": ["eng"], "ELocationID": ["10.2147/IJN.S213831"], "Journal": {"ISSN": "1178-2013", "JournalIssue": {"Volume": "14", "PubDate": {"Year": "2019"}}, "Title": "International journal of nanomedicine", "ISOAbbreviation": "Int J Nanomedicine"}, "ArticleTitle": "Nanoformulations of natural products for management of metabolic syndrome.", "Pagination": {"StartPage": "5303", "EndPage": "5321", "MedlinePgn": "5303-5321"}, "Abstract": {"AbstractText": ["Metabolic syndrome is a common metabolic disorder which has become a public health challenge worldwide. There has been growing interest in medications including natural products as complementary or alternative choices for common chemical therapeutics regarding their limited side effects and ease of access. Nanosizing these compounds may help to increase their solubility, bioavailability, and promisingly enhance their efficacy. This study, for the first time, provides a comprehensive overview of the application of natural-products-based nanoformulations in the management of metabolic syndrome. Different phytochemicals including curcumin, berberine, Capsicum oleoresin, naringenin, emodin, gymnemic acid, resveratrol, quercetin, scutellarin, stevioside, silybin, baicalin, and others have been nanosized hitherto, and their nanosizing method and effect in treatment and alleviating metabolic syndrome have been reviewed and discussed in this study. It has been discovered that there are several pathways or molecular targets relevant to metabolic disorders which are affected by these compounds. Various natural-based nanoformulations have shown promising effect in treatment of metabolic syndrome, and therefore can be considered as future candidates instead of or in conjunction with pharmaceutical drugs if they pass clinical trials successfully."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Nanotechnology, School of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran."}, {"Identifier": [], "Affiliation": "Phytopharmacology Interest Group (PPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran."}, {"Identifier": [], "Affiliation": "Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran."}], "LastName": "Taghipour", "ForeName": "Yasamin Davatgaran", "Initials": "YD"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran."}], "LastName": "Hajialyani", "ForeName": "Marziyeh", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Internal Medicine Department, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran."}], "LastName": "Naseri", "ForeName": "Rozita", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran."}], "LastName": "Hesari", "ForeName": "Mahvash", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran."}], "LastName": "Mohammadi", "ForeName": "Pantea", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, G. d'Annunzio University of Chieti-pescara, Chieti 66100, Italy."}], "LastName": "Stefanucci", "ForeName": "Azzurra", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, G. d'Annunzio University of Chieti-pescara, Chieti 66100, Italy."}], "LastName": "Mollica", "ForeName": "Adriano", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran."}, {"Identifier": [], "Affiliation": "Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran."}], "LastName": "Farzaei", "ForeName": "Mohammad Hosein", "Initials": "MH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toxicology and Diseases Group, the Institute of Pharmaceutical Sciences (TIPS) and Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), Tehran, Iran."}], "LastName": "Abdollahi", "ForeName": "Mohammad", "Initials": "M"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Int J Nanomedicine", "NlmUniqueID": "101263847", "ISSNLinking": "1176-9114"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Biological Products"}], "MeshHeadingList": [{"QualifierName": ["therapeutic use"], "DescriptorName": "Biological Products"}, {"QualifierName": [], "DescriptorName": "Drug Compounding"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy", "physiopathology"], "DescriptorName": "Metabolic Syndrome"}, {"QualifierName": ["chemistry"], "DescriptorName": "Nanoparticles"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Translational Research, Biomedical"}], "CoiStatement": "The authors report no conflicts of interest in this work."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Tabatabaei-Malazy O, Larijani B, Abdollahi M. Targeting metabolic disorders by natural products. J Diabetes Metab Disord. 2015;14:57. doi:10.1186/s40200-015-0184-8", "ArticleIdList": ["10.1186/s40200-015-0184-8", "PMC4495701", "26157708"]}, {"Citation": "McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018;36(1):14\u201320. doi:10.1016/j.clindermatol.2017.09.004", "ArticleIdList": ["10.1016/j.clindermatol.2017.09.004", "29241747"]}, {"Citation": "Swarup S, Zeltser R. Metabolic syndrome In: StatPearls [internet]. StatPearls Publishing; 2018.", "ArticleIdList": ["29083742"]}, {"Citation": "Deen D. Metabolic syndrome: time for action. Am Fam Physician. 2004;69:12.", "ArticleIdList": ["15222652"]}, {"Citation": "Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014. doi:10.1155/2014/943162", "ArticleIdList": ["10.1155/2014/943162", "PMC3966331", "24711954"]}, {"Citation": "Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2006;58(14):1532\u20131555. doi:10.1016/j.addr.2006.09.009", "ArticleIdList": ["10.1016/j.addr.2006.09.009", "17092599"]}, {"Citation": "Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 2012;64:37\u201348. doi:10.1016/j.addr.2012.09.013", "ArticleIdList": ["10.1016/j.addr.2012.09.013", "11251249"]}, {"Citation": "Lann D, LeRoith D. Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am. 2007;91(6):1063\u20131077, viii. doi:10.1016/j.mcna.2007.06.012", "ArticleIdList": ["10.1016/j.mcna.2007.06.012", "17964909"]}, {"Citation": "Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet (London, England). 2005;365(9468):1415\u20131428. doi:10.1016/S0140-6736(05)66378-7", "ArticleIdList": ["10.1016/S0140-6736(05)66378-7", "15836891"]}, {"Citation": "Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol. 2013;3(1):1\u201358. doi:10.1002/cphy.c110062", "ArticleIdList": ["10.1002/cphy.c110062", "PMC4129661", "23720280"]}, {"Citation": "Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007;87(2):507\u2013520. doi:10.1152/physrev.00024.2006", "ArticleIdList": ["10.1152/physrev.00024.2006", "PMC2995548", "17429039"]}, {"Citation": "Kim DH, Perdomo G, Zhang T, et al. FoxO6 integrates insulin signaling with gluconeogenesis in the liver. Diabetes. 2011;60(11):2763\u20132774. doi:10.2337/db11-0548", "ArticleIdList": ["10.2337/db11-0548", "PMC3198083", "21940782"]}, {"Citation": "Meyer MM, Levin K, Grimmsmann T, Beck-Nielsen H, Klein HH. Insulin signalling in skeletal muscle of subjects with or without type II-diabetes and first degree relatives of patients with the disease. Diabetologia. 2002;45(6):813\u2013822. doi:10.1007/s00125-002-0830-9", "ArticleIdList": ["10.1007/s00125-002-0830-9", "12107725"]}, {"Citation": "Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7(2):85\u201396. doi:10.1038/nrm1837", "ArticleIdList": ["10.1038/nrm1837", "16493415"]}, {"Citation": "Saha SS, Ghosh M. Antioxidant and anti-inflammatory effect of conjugated linolenic acid isomers against streptozotocin-induced diabetes. Br J Nutr. 2012;108(6):974\u2013983. doi:10.1017/S0007114511006325", "ArticleIdList": ["10.1017/S0007114511006325", "22182422"]}, {"Citation": "Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799\u2013806. doi:10.1038/414799a", "ArticleIdList": ["10.1038/414799a", "11742412"]}, {"Citation": "Lizcano JM, Alessi DR. The insulin signalling pathway. Curr Biol. 2002;12(7):R236\u2013R238.", "ArticleIdList": ["11937037"]}, {"Citation": "Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol. 2002;3(4):267\u2013277. doi:10.1038/nrm782", "ArticleIdList": ["10.1038/nrm782", "11994746"]}, {"Citation": "Patel TP, Rawal K, Bagchi AK, et al. Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes. Heart Fail Rev. 2016;21(1):11\u201323. doi:10.1007/s10741-015-9515-6", "ArticleIdList": ["10.1007/s10741-015-9515-6", "26542377"]}, {"Citation": "Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017;11(8):215\u2013225. doi:10.1177/1753944717711379", "ArticleIdList": ["10.1177/1753944717711379", "PMC5933580", "28639538"]}, {"Citation": "Tooke JE, Hannemann MM. Adverse endothelial function and the insulin resistance syndrome. J Intern Med. 2000;247(4):425\u2013431.", "ArticleIdList": ["10792555"]}, {"Citation": "Halpern A, Mancini MC, Magalhaes ME, et al. Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment. Diabetol Metab Syndr. 2010;2:55. doi:10.1186/1758-5996-2-55", "ArticleIdList": ["10.1186/1758-5996-2-55", "PMC2939537", "20718958"]}, {"Citation": "Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162. doi:10.1155/2014/943162", "ArticleIdList": ["10.1155/2014/943162", "PMC3966331", "24711954"]}, {"Citation": "Bonner G. Hyperinsulinemia, insulin resistance, and hypertension. J Cardiovasc Pharmacol. 1994;24(Suppl 2):S39\u2013S49.", "ArticleIdList": ["7898093"]}, {"Citation": "Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol. 2004;286(5):H1597\u2013H1602. doi:10.1152/ajpheart.00026.2004", "ArticleIdList": ["10.1152/ajpheart.00026.2004", "15072967"]}, {"Citation": "Yanai H, Tomono Y, Ito K, Furutani N, Yoshida H, Tada N. The underlying mechanisms for development of hypertension in the metabolic syndrome. Nutr J. 2008;7:10. doi:10.1186/1475-2891-7-10", "ArticleIdList": ["10.1186/1475-2891-7-10", "PMC2335113", "18416854"]}, {"Citation": "Ribeiro-Oliveira A Jr, Nogueira AI, Pereira RM, Boas WW, Dos Santos RA, Silva ACS. The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag. 2008;4(4):787\u2013803.", "ArticleIdList": ["PMC2597759", "19065996"]}, {"Citation": "Hsueh WA, Quinones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol. 2003;92(4A):10J\u201317J. doi:10.1016/s0002-9149(03)00611-8", "ArticleIdList": ["10.1016/s0002-9149(03)00611-8", "12957322"]}, {"Citation": "Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost. 2003;1(7):1575\u20131579.", "ArticleIdList": ["12871293"]}, {"Citation": "Russo I. The prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balance. Scientifica. 2012;2012:525374. doi:10.6064/2012/525374", "ArticleIdList": ["10.6064/2012/525374", "PMC3820496", "24278711"]}, {"Citation": "Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19(4):972\u2013978.", "ArticleIdList": ["10195925"]}, {"Citation": "Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548\u20132556. doi:10.1210/jc.2004-0395", "ArticleIdList": ["10.1210/jc.2004-0395", "15181022"]}, {"Citation": "Atanasov AG, Waltenberger B, Pferschy-Wenzig E-M, et al. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33(8):1582\u20131614. doi:10.1016/j.biotechadv.2015.08.001", "ArticleIdList": ["10.1016/j.biotechadv.2015.08.001", "PMC4748402", "26281720"]}, {"Citation": "Cefalu WT, Ye J, Wang ZQ. Efficacy of dietary supplementation with botanicals on carbohydrate metabolism in humans. Endocr Metab Immune Disord Drug Targets. 2008;8(2):78\u201381. doi:10.2174/187153008784534376", "ArticleIdList": ["10.2174/187153008784534376", "18537692"]}, {"Citation": "Dong H, Lu FE, Zhao L. Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease. Chin J Integr Med. 2012;18(2):152\u2013160. doi:10.1007/s11655-012-0993-2", "ArticleIdList": ["10.1007/s11655-012-0993-2", "22311412"]}, {"Citation": "Heber D. Herbs and atherosclerosis. Curr Atheroscler Rep. 2001;3(1):93\u201396.", "ArticleIdList": ["11123854"]}, {"Citation": "Alzahrani T, Marrat S, Haider A. Management of dyslipidemia in primary care. Can J Cardiol. 2003;19(13):1499\u20131502.", "ArticleIdList": ["14760440"]}, {"Citation": "Bays H, Stein EA. Pharmacotherapy for dyslipidaemia\u2013current therapies and future agents. Expert Opin Pharmacother. 2003;4(11):1901\u20131938. doi:10.1517/14656566.4.11.1901", "ArticleIdList": ["10.1517/14656566.4.11.1901", "14596646"]}, {"Citation": "Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113\u20131132. doi:10.1016/j.jacc.2010.05.034", "ArticleIdList": ["10.1016/j.jacc.2010.05.034", "20863953"]}, {"Citation": "Waltenberger B, Mocan A, \u0160mejkal K, Heiss EH, Atanasov AG. Natural products to counteract the epidemic of cardiovascular and metabolic disorders. Molecules. 2016;21:6. doi:10.3390/molecules21060807", "ArticleIdList": ["10.3390/molecules21060807", "PMC4928700", "27338339"]}, {"Citation": "R\u00edos JL, Francini F, Schinella GR. Natural products for the treatment of type 2 diabetes mellitus. Planta Med. 2015;81(12/13):975\u2013994. doi:10.1055/s-0035-1546131", "ArticleIdList": ["10.1055/s-0035-1546131", "26132858"]}, {"Citation": "Lacroix IM, Li-Chan EC. Overview of food products and dietary constituents with antidiabetic properties and their putative mechanisms of action: a natural approach to complement pharmacotherapy in the management of diabetes. Mol Nutr Food Res. 2014;58(1):61\u201378. doi:10.1002/mnfr.201300223", "ArticleIdList": ["10.1002/mnfr.201300223", "23943383"]}, {"Citation": "Hung HY, Qian K, Morris-Natschke SL, Hsu CS, Lee KH. Recent discovery of plant-derived anti-diabetic natural products. Nat Prod Rep. 2012;29(5):580\u2013606. doi:10.1039/c2np00074a", "ArticleIdList": ["10.1039/c2np00074a", "22491825"]}, {"Citation": "Gautam R, Jachak SM. Recent developments in anti-inflammatory natural products. Med Res Rev. 2009;29(5):767\u2013820. doi:10.1002/med.20156", "ArticleIdList": ["10.1002/med.20156", "19378317"]}, {"Citation": "Hermansen K, Dinesen B, Hoie LH, Morgenstern E, Gruenwald J. Effects of soy and other natural products on LDL:HDL ratio and other lipid parameters: a literature review. Adv Ther. 2003;20(1):50\u201378.", "ArticleIdList": ["12772818"]}, {"Citation": "Vasanthi HR, ShriShriMal N, Das DK. Phytochemicals from plants to combat cardiovascular disease. Curr Med Chem. 2012;19(14):2242\u20132251.", "ArticleIdList": ["22414106"]}, {"Citation": "Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflammation Res. 2000;49(10):497\u2013505. doi:10.1007/s000110050622", "ArticleIdList": ["10.1007/s000110050622", "11089900"]}, {"Citation": "Francis GA, Annicotte JS, Auwerx J. PPAR agonists in the treatment of atherosclerosis. Curr Opin Pharmacol. 2003;3(2):186\u2013191.", "ArticleIdList": ["12681242"]}, {"Citation": "Varga T, Czimmerer Z, Nagy L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta. 2011;1812(8):1007\u20131022. doi:10.1016/j.bbadis.2011.02.014", "ArticleIdList": ["10.1016/j.bbadis.2011.02.014", "PMC3117990", "21382489"]}, {"Citation": "Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology. 2003;144(6):2201\u20132207. doi:10.1210/en.2003-0288", "ArticleIdList": ["10.1210/en.2003-0288", "12746275"]}, {"Citation": "Gurnell M, Savage DB, Chatterjee VK, O\u2019Rahilly S. The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab. 2003;88(6):2412\u20132421. doi:10.1210/jc.2003-030435", "ArticleIdList": ["10.1210/jc.2003-030435", "12788836"]}, {"Citation": "Francis GA, Annicotte JS, Auwerx J. PPAR-alpha effects on the heart and other vascular tissues. Am J Physiol Heart Circ Physiol. 2003;285(1):H1\u2013H9. doi:10.1152/ajpheart.01118.2002", "ArticleIdList": ["10.1152/ajpheart.01118.2002", "12623780"]}, {"Citation": "Miller AR, Etgen GJ. Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome. Expert Opin Investig Drugs. 2003;12(9):1489\u20131500. doi:10.1517/13543784.12.9.1489", "ArticleIdList": ["10.1517/13543784.12.9.1489", "12943493"]}, {"Citation": "Huang TH, Kota BP, Razmovski V, Roufogalis BD. Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome. Basic Clin Pharmacol Toxicol. 2005;96(1):3\u201314. doi:10.1111/j.1742-7843.2005.pto960102.x", "ArticleIdList": ["10.1111/j.1742-7843.2005.pto960102.x", "15667590"]}, {"Citation": "Jaradat MS, Noonan DJ, Wu B, Avery MA, Feller DR. Pseudolaric acid analogs as a new class of peroxisome proliferator-activated receptor agonists. Planta Med. 2002;68(8):667\u2013671. doi:10.1055/s-2002-33785", "ArticleIdList": ["10.1055/s-2002-33785", "12221584"]}, {"Citation": "Yoon M, Lee H, Jeong S, et al. Peroxisome proliferator-activated receptor alpha is involved in the regulation of lipid metabolism by ginseng. Br J Pharmacol. 2003;138(7):1295\u20131302. doi:10.1038/sj.bjp.0705169", "ArticleIdList": ["10.1038/sj.bjp.0705169", "PMC1573779", "12711630"]}, {"Citation": "Yang Y, Wu T, He K, Fu ZG. Effect of aerobic exercise and ginsenosides on lipid metabolism in diet-induced hyperlipidemia mice. Zhongguo Yao Li Xue Bao. 1999;20(6):563\u2013565.", "ArticleIdList": ["10678155"]}, {"Citation": "Kim SH, Park KS. Effects of panax ginseng extract on lipid metabolism in humans. Pharmacological Res. 2003;48(5):511\u2013513.", "ArticleIdList": ["12967598"]}, {"Citation": "Dang ZC, Audinot V, Papapoulos SE, Boutin JA, Lowik CW. Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein. J Biol Chem. 2003;278(2):962\u2013967. doi:10.1074/jbc.M209483200", "ArticleIdList": ["10.1074/jbc.M209483200", "12421816"]}, {"Citation": "Shi Y. Orphan nuclear receptors in drug discovery. Drug Discov Today. 2007;12(11\u201312):440\u2013445. doi:10.1016/j.drudis.2007.04.006", "ArticleIdList": ["10.1016/j.drudis.2007.04.006", "PMC2748783", "17532527"]}, {"Citation": "Bramlett KS, Houck KA, Borchert KM, et al. A natural product ligand of the oxysterol receptor, liver X receptor. J Pharmacol Exp Ther. 2003;307(1):291\u2013296. doi:10.1124/jpet.103.052852", "ArticleIdList": ["10.1124/jpet.103.052852", "12893846"]}, {"Citation": "Chiang JY. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol. 2004;40(3):539\u2013551. doi:10.1016/j.jhep.2003.11.006", "ArticleIdList": ["10.1016/j.jhep.2003.11.006", "15123373"]}, {"Citation": "Urizar NL, Moore DD. GUGULIPID: a natural cholesterol-lowering agent. Annu Rev Nutr. 2003;23:303\u2013313. doi:10.1146/annurev.nutr.23.011702.073102", "ArticleIdList": ["10.1146/annurev.nutr.23.011702.073102", "12626688"]}, {"Citation": "Davatgaran-Taghipour Y, Masoomzadeh S, Farzaei MH, et al. Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective. Int J Nanomedicine. 2017;12:2689. doi:10.2147/IJN.S131973", "ArticleIdList": ["10.2147/IJN.S131973", "PMC5388197", "28435252"]}, {"Citation": "Rachmawati H, SORAYA I, Kurniati N, Rahma A. In vitro study on antihypertensive and antihypercholesterolemic effects of a curcumin nanoemulsion. Sci Pharm. 2016;84(1):131\u2013140. doi:10.3797/scipharm.ISP.2015.05", "ArticleIdList": ["10.3797/scipharm.ISP.2015.05", "PMC4839556", "27110504"]}, {"Citation": "Taghipour YD, Bahramsoltani R, Marques AM, et al. A systematic review of nano formulation of natural products for the treatment of inflammatory bowel disease: drug delivery and pharmacological targets. DARU J Pharm Sci. 2018;26(2):229\u2013239.", "ArticleIdList": ["PMC6279665", "30382546"]}, {"Citation": "Soetikno V, Sari FR, Veeraveedu PT, et al. Curcumin ameliorates macrophage infiltration by inhibiting NF-\u03baB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr Metab (Lond). 2011;8(1):35. doi:10.1186/1743-7075-8-35", "ArticleIdList": ["10.1186/1743-7075-8-35", "PMC3123175", "21663638"]}, {"Citation": "Aggarwal BB. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr. 2010;30:173\u2013199. doi:10.1146/annurev.nutr.012809.104755", "ArticleIdList": ["10.1146/annurev.nutr.012809.104755", "PMC3144156", "20420526"]}, {"Citation": "Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem. 1995;270(42):24995\u201325000. doi:10.1074/jbc.270.42.24995", "ArticleIdList": ["10.1074/jbc.270.42.24995", "7559628"]}, {"Citation": "Xu J, Fu Y, Chen A. Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol Gastrointest Liver Physiol. 2003;285(1):G20\u2013G30. doi:10.1152/ajpgi.00474.2002", "ArticleIdList": ["10.1152/ajpgi.00474.2002", "12660143"]}, {"Citation": "Gonzalez-Castejon M, Rodriguez-Casado A. Dietary phytochemicals and their potential effects on obesity: a review. Pharmacological Res. 2011;64(5):438\u2013455.", "ArticleIdList": ["21798349"]}, {"Citation": "Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as \u201cCurecumin\u201d: from kitchen to clinic. Biochem Pharmacol. 2008;75(4):787\u2013809. doi:10.1016/j.bcp.2007.08.016", "ArticleIdList": ["10.1016/j.bcp.2007.08.016", "17900536"]}, {"Citation": "Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65(11):1631\u20131652. doi:10.1007/s00018-008-7452-4", "ArticleIdList": ["10.1007/s00018-008-7452-4", "PMC4686230", "18324353"]}, {"Citation": "Wahlstr\u00f6m B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh). 1978;43(2):86\u201392.", "ArticleIdList": ["696348"]}, {"Citation": "Ernest U, Chen H-Y, Xu M-J, et al. Anti-cancerous potential of polyphenol-loaded polymeric nanotherapeutics. Molecules. 2018;23(11):2787. doi:10.3390/molecules23112787", "ArticleIdList": ["10.3390/molecules23112787", "PMC6278361", "30373235"]}, {"Citation": "Hajialyani M, Tewari D, Sobarzo-S\u00e1nchez E, Nabavi SM, Farzaei MH, Abdollahi M. Natural product-based nanomedicines for wound healing purposes: therapeutic targets and drug delivery systems. Int J Nanomedicine. 2018;13:5023\u20135043. doi:10.2147/IJN.S174072", "ArticleIdList": ["10.2147/IJN.S174072", "PMC6128268", "30214204"]}, {"Citation": "Tong F, Chai R, Jiang H, Dong B. In vitro/vivo drug release and anti-diabetic cardiomyopathy properties of curcumin/PBLG-PEG-PBLG nanoparticles. Int J Nanomedicine. 2018;13:1945. doi:10.2147/IJN.S177627", "ArticleIdList": ["10.2147/IJN.S177627", "PMC5892954", "29662310"]}, {"Citation": "Joshi RP, Negi G, Kumar A, et al. SNEDDS curcumin formulation leads to enhanced protection from pain and functional deficits associated with diabetic neuropathy: an insight into its mechanism for neuroprotection. Nanomed. 2013;9(6):776\u2013785. doi:10.1016/j.nano.2013.01.001", "ArticleIdList": ["10.1016/j.nano.2013.01.001", "23347896"]}, {"Citation": "Grama CN, Suryanarayana P, Patil MA, et al. Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model. PLoS One. 2013;8(10):e78217. doi:10.1371/journal.pone.0078217", "ArticleIdList": ["10.1371/journal.pone.0078217", "PMC3796473", "24155984"]}, {"Citation": "El-Far YM, Zakaria MM, Gabr MM, El Gayar AM, Eissa LA, El-Sherbiny IM. Nanoformulated natural therapeutics for management of streptozotocin-induced diabetes: potential use of curcumin nanoformulation. Nanomedicine. 2017;12(14):1689\u20131711. doi:10.2217/nnm-2017-0106", "ArticleIdList": ["10.2217/nnm-2017-0106", "28635562"]}, {"Citation": "Devadasu VR, Wadsworth RM, Kumar MR. Protective effects of nanoparticulate coenzyme Q 10 and curcumin on inflammatory markers and lipid metabolism in streptozotocin-induced diabetic rats: a possible remedy to diabetic complications. Drug Deliv Transl Res. 2011;1(6):448\u2013455. doi:10.1007/s13346-011-0041-3", "ArticleIdList": ["10.1007/s13346-011-0041-3", "25786365"]}, {"Citation": "Rachmawati H, Soraya IS, Kurniati NF, Rahma A. In vitro study on antihypertensive and antihypercholesterolemic effects of a curcumin nanoemulsion. Sci Pharm. 2016;84(1):131\u2013140. doi:10.3797/scipharm.ISP.2015.05", "ArticleIdList": ["10.3797/scipharm.ISP.2015.05", "PMC4839556", "27110504"]}, {"Citation": "Jia T, Rao J, Zou L, et al. Nanoparticle-encapsulated curcumin inhibits diabetic neuropathic pain involving the P2Y12 receptor in the dorsal root ganglia. Front Neurosci. 2018;11:755. doi:10.3389/fnins.2017.00755", "ArticleIdList": ["10.3389/fnins.2017.00755", "PMC5788895", "29422835"]}, {"Citation": "Liu J, Chen Z, Wang J, et al. Encapsulation of curcumin nanoparticles with MMP9-responsive and thermos-sensitive hydrogel improves diabetic wound healing. ACS Appl Mater Interfaces. 2018;10(19):16315\u201316326. doi:10.1021/acsami.8b03868", "ArticleIdList": ["10.1021/acsami.8b03868", "29687718"]}, {"Citation": "Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today. 2012;17(1\u20132):71\u201380. doi:10.1016/j.drudis.2011.09.009", "ArticleIdList": ["10.1016/j.drudis.2011.09.009", "PMC3259195", "21959306"]}, {"Citation": "Yallapu MM, Jaggi M, Chauhan CS. Curcumin nanomedicine: a road to cancer therapeutics. Curr Pharm Des. 2013;19(11):1994\u20132010.", "ArticleIdList": ["PMC3640558", "23116309"]}, {"Citation": "Melgar-Lalanne G, Hern\u00e1ndez-\u00c1lvarez AJ, Jim\u00e9nez-Fern\u00e1ndez M, Azuara E. Oleoresins from capsicum spp.: extraction methods and bioactivity. Food Bioproc Tech. 2017;10(1):51\u201376. doi:10.1007/s11947-016-1793-z", "ArticleIdList": ["10.1007/s11947-016-1793-z"]}, {"Citation": "Dwivedi V, Shrivastava R, Hussain S, Ganguly C, Bharadwaj M. Cytotoxic potential of Indian spices (extracts) against esophageal squamous carcinoma cells. Asian Pac J Cancer Prev. 2011;12(8):2069\u20132073.", "ArticleIdList": ["22292653"]}, {"Citation": "Allemand A, Leonardi BF, Zimmer AR, Moreno S, Romao PRT, Gosmann G. Red pepper (Capsicum baccatum) extracts present anti-inflammatory effects in vivo and inhibit the production of TNF-\u03b1 and NO in vitro. J Med Food. 2016;19(8):759\u2013767. doi:10.1089/jmf.2015.0101", "ArticleIdList": ["10.1089/jmf.2015.0101", "27533650"]}, {"Citation": "Kim J-Y, Lee M-S, Jung S, et al. Anti-obesity efficacy of nanoemulsion oleoresin capsicum in obese rats fed a high-fat diet. Int J Nanomedicine. 2014;9:301. doi:10.2147/IJN.S52414", "ArticleIdList": ["10.2147/IJN.S52414", "PMC3883587", "24403834"]}, {"Citation": "Lee M-S, Jung S, Shin Y, et al. Lipolytic efficacy of alginate double-layer nanoemulsion containing oleoresin capsicum in differentiated 3T3-L1 adipocytes. Food Nutr Res. 2017;61(1):1339553. doi:10.1080/16546628.2017.1339553", "ArticleIdList": ["10.1080/16546628.2017.1339553", "PMC5510203", "28747860"]}, {"Citation": "Wang N, Tan H-Y, Li L, Yuen M-F, Feng Y. Berberine and coptidis rhizoma as potential anticancer agents: recent updates and future perspectives. J Ethnopharmacol. 2015;176:35\u201348. doi:10.1016/j.jep.2015.10.028", "ArticleIdList": ["10.1016/j.jep.2015.10.028", "26494507"]}, {"Citation": "Bao J, Huang B, Zou L, et al. Hormetic effect of berberine attenuates the anticancer activity of chemotherapeutic agents. PLoS One. 2015;10(9):e0139298. doi:10.1371/journal.pone.0139298", "ArticleIdList": ["10.1371/journal.pone.0139298", "PMC4589364", "26421434"]}, {"Citation": "Li M, Zhang M, Zhang Z-L, et al. Induction of apoptosis by berberine in hepatocellular carcinoma HepG2 cells via downregulation of NF-\u03baB. Oncol Res Featuring Preclinical Clin Cancer Ther. 2017;25(2):233\u2013239. doi:10.3727/096504016X14742891049073", "ArticleIdList": ["10.3727/096504016X14742891049073", "PMC7840840", "28277195"]}, {"Citation": "Yang J, Yin J, Gao H, et al. Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients. Evid Based Complement Alternat Med. 2012;2012. doi:10.1155/2012/363845", "ArticleIdList": ["10.1155/2012/363845", "PMC3310165", "22474499"]}, {"Citation": "Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55(8):2256\u20132264. doi:10.2337/db06-0006", "ArticleIdList": ["10.2337/db06-0006", "16873688"]}, {"Citation": "P\u00e9rez-Rubio KG, Gonz\u00e1lez-Ortiz M, Mart\u00ednez-Abundis E, Robles-Cervantes JA, Espinel-Berm\u00fadez MC. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2013;11(5):366\u2013369. doi:10.1089/met.2012.0183", "ArticleIdList": ["10.1089/met.2012.0183", "23808999"]}, {"Citation": "Xue M, Yang M-X, Zhang W, et al. Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. Int J Nanomedicine. 2013;8:4677. doi:10.2147/IJN.S37465", "ArticleIdList": ["10.2147/IJN.S37465", "PMC3862509", "24353417"]}, {"Citation": "Kapoor R, Singh S, Tripathi M, Bhatnagar P, Kakkar P, Gupta KC. O-hexadecyl-dextran entrapped berberine nanoparticles abrogate high glucose stress induced apoptosis in primary rat hepatocytes. PLoS One. 2014;9(2):e89124. doi:10.1371/journal.pone.0089124", "ArticleIdList": ["10.1371/journal.pone.0089124", "PMC3930636", "24586539"]}, {"Citation": "Ochin CC, Garelnabi M. Berberine encapsulated PLGA-PEG nanoparticles modulate PCSK-9 in HepG2 cells. Cardiovasc Hematol Disord Drug Targets. 2018;18(1):61\u201370. doi:10.2174/1871529X18666180201130340", "ArticleIdList": ["10.2174/1871529X18666180201130340", "29422010"]}, {"Citation": "Cavia-Saiz M, Busto MD, Pilar-Izquierdo MC, Ortega N, Perez-Mateos M, Mu\u00f1iz P. Antioxidant properties, radical scavenging activity and biomolecule protection capacity of flavonoid naringenin and its glycoside naringin: a comparative study. J Sci Food Agric. 2010;90(7):1238\u20131244. doi:10.1002/jsfa.3959", "ArticleIdList": ["10.1002/jsfa.3959", "20394007"]}, {"Citation": "Ortiz-Andrade RR, S\u00e1nchez-Salgado JC, Navarrete-V\u00e1zquez G, et al. Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra-pancreatic glucose regulation. Diabetes Metab Syndr Obes. 2008;10(11):1097\u20131104. doi:10.1111/j.1463-1326.2008.00869.x", "ArticleIdList": ["10.1111/j.1463-1326.2008.00869.x", "18355329"]}, {"Citation": "Prabu SM, Renugadevi J, Shagirtha K. In vivo and in vitro antioxidative efficacy of naringenin on cadmium-induced toxicity in rats. Res Rev. 2019;3(3):9\u201316."}, {"Citation": "Scalbert A, R\u00e9m\u00e9sy C, Morand C, Jim\u00e9nez L, Manach C. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004;79(5):727\u2013747. doi:10.1093/ajcn/79.5.727", "ArticleIdList": ["10.1093/ajcn/79.5.727", "15113710"]}, {"Citation": "Maity S, Mukhopadhyay P, Kundu PP, Chakraborti AS. Alginate coated chitosan core-shell nanoparticles for efficient oral delivery of naringenin in diabetic animals\u2014an in vitro and in vivo approach. Carbohydr Polym. 2017;170:124\u2013132. doi:10.1016/j.carbpol.2017.04.066", "ArticleIdList": ["10.1016/j.carbpol.2017.04.066", "28521977"]}, {"Citation": "Hashemzaei M, Delarami Far A, Yari A, et al. Anticancer and apoptosis\u2011inducing effects of quercetin in vitro and in vivo. Oncol Rep. 2017;38(2):819\u2013828. doi:10.3892/or.2017.5766", "ArticleIdList": ["10.3892/or.2017.5766", "PMC5561933", "28677813"]}, {"Citation": "Leiherer A, Stoemmer K, Muendlein A, et al. Quercetin impacts expression of metabolism-and obesity-associated genes in SGBS adipocytes. Nutrients. 2016;8(5):282. doi:10.3390/nu8050282", "ArticleIdList": ["10.3390/nu8050282", "PMC4882695", "27187453"]}, {"Citation": "Rivera L, Mor\u00f3n R, S\u00e1nchez M, Zarzuelo A, Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese zucker rats. Obesity. 2008;16(9):2081\u20132087. doi:10.1038/oby.2008.315", "ArticleIdList": ["10.1038/oby.2008.315", "18551111"]}, {"Citation": "Hasani-Ranjbar S, Larijani B, Abdollahi M. A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases. Inflamm Allergy Drug Targets. 2009;8(1):2\u201310.", "ArticleIdList": ["19275687"]}, {"Citation": "Mitjavila M, Moreno J. The effects of polyphenols on oxidative stress and the arachidonic acid cascade. Implications for the prevention/treatment of high prevalence diseases. Biochem Pharmacol. 2012;84(9):1113\u20131122. doi:10.1016/j.bcp.2012.07.017", "ArticleIdList": ["10.1016/j.bcp.2012.07.017", "22858365"]}, {"Citation": "Abdollahi M, Tabatabaei-Malazy O, Larijani B. A systematic review of in vitro studies conducted on effect of herbal products on secretion of insulin from Langerhans islets. J Pharm Pharm Sci. 2012;15(3):447\u2013466. doi:10.18433/J32W29", "ArticleIdList": ["10.18433/J32W29", "23148894"]}, {"Citation": "Pfeuffer M, Auinger A, Bley U, et al. Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammation in men with different APOE isoforms. Nutr Metab Cardiovasc Dis. 2013;23(5):403\u2013409. doi:10.1016/j.numecd.2011.08.010", "ArticleIdList": ["10.1016/j.numecd.2011.08.010", "22118955"]}, {"Citation": "Tong F, Liu S, Yan B, Li X, Ruan S, Yang S. Quercetin nanoparticle complex attenuated diabetic nephropathy via regulating the expression level of ICAM-1 on endothelium. Int J Nanomedicine. 2017;12:7799. doi:10.2147/IJN.S146978", "ArticleIdList": ["10.2147/IJN.S146978", "PMC5661459", "29123394"]}, {"Citation": "Mukhopadhyay P, Maity S, Mandal S, Chakraborti AS, Prajapati A, Kundu P. Preparation, characterization and in vivo evaluation of pH sensitive, safe quercetin-succinylated chitosan-alginate core-shell-corona nanoparticle for diabetes treatment. Carbohydr Polym. 2018;182:42\u201351. doi:10.1016/j.carbpol.2017.10.098", "ArticleIdList": ["10.1016/j.carbpol.2017.10.098", "29279124"]}, {"Citation": "Schwingel TE, Klein CP, Nicoletti NF, et al. Effects of the compounds resveratrol, rutin, quercetin, and quercetin nanoemulsion on oxaliplatin-induced hepatotoxicity and neurotoxicity in mice. Naunyn Schmiedebergs Arch Pharmacol. 2014;387(9):837\u2013848. doi:10.1007/s00210-014-0994-0", "ArticleIdList": ["10.1007/s00210-014-0994-0", "24908156"]}, {"Citation": "Chitkara D, Nikalaje SK, Mittal A, Chand M, Kumar N. Development of quercetin nanoformulation and in vivo evaluation using streptozotocin induced diabetic rat model. Drug Deliv Transl Res. 2012;2(2):112\u2013123. doi:10.1007/s13346-012-0063-5", "ArticleIdList": ["10.1007/s13346-012-0063-5", "25786720"]}, {"Citation": "Alam MM, Abdullah K, Singh BR, Naqvi AH, Naseem I. Ameliorative effect of quercetin nanorods on diabetic mice: mechanistic and therapeutic strategies. RSC Adv. 2016;6(60):55092\u201355103. doi:10.1039/C6RA04821H", "ArticleIdList": ["10.1039/C6RA04821H"]}, {"Citation": "Jayasuriya H, Koonchanok NM, Geahlen RL, McLaughlin JL, Chang C-J. Emodin, a protein tyrosine kinase inhibitor from polygonum cuspidatum. J Nat Prod. 1992;55(5):696\u2013698.", "ArticleIdList": ["1517743"]}, {"Citation": "Dong X, Fu J, Yin X, et al. Emodin: a review of its pharmacology, toxicity and pharmacokinetics. Phytotherapy Research. 2016;30(8):1207\u20131218. doi:10.1002/ptr.5631", "ArticleIdList": ["10.1002/ptr.5631", "PMC7168079", "27188216"]}, {"Citation": "Li L, Sheng X, Zhao S, et al. Nanoparticle-encapsulated emodin decreases diabetic neuropathic pain probably via a mechanism involving P2X3 receptor in the dorsal root ganglia. Purinergic Signal. 2017;13(4):559\u2013568. doi:10.1007/s11302-017-9583-2", "ArticleIdList": ["10.1007/s11302-017-9583-2", "PMC5714846", "28840511"]}, {"Citation": "Lu K, Xie S, Han S, et al. Preparation of a nano emodin transfersome and study on its anti-obesity mechanism in adipose tissue of diet-induced obese rats. J Transl Med. 2014;12(1):72. doi:10.1186/1479-5876-12-72", "ArticleIdList": ["10.1186/1479-5876-12-72", "PMC3994574", "24641917"]}, {"Citation": "Patel K, Gadewar M, Tripathi R. Pharmacological and analytical aspects of gymnemic acid: a concise report. Asian Pac J Trop Dis. 2012;2(5):414\u2013416. doi:10.1016/S2222-1808(12)60090-5", "ArticleIdList": ["10.1016/S2222-1808(12)60090-5", "0"]}, {"Citation": "Ankit S, Chetan S, Aneja KR, Rakesh P. Gymnema sylvestre (Gurmar): a review. Der Pharmacia Lettre. 2010;2(1):275\u2013284."}, {"Citation": "Ravichandran R. Studies on gymnemic acids nanoparticulate formulations against diabetes mellitus. Int J Biomed Clin Eng. 2012;1(2):1\u201312. doi:10.4018/IJBCE", "ArticleIdList": ["10.4018/IJBCE"]}, {"Citation": "Waisundara VY, Hsu A, Tan BK, Huang D. Baicalin improves antioxidant status of streptozotocin-induced diabetic wistar rats. J Agric Food Chem. 2009;57(10):4096\u20134102. doi:10.1021/jf8028539", "ArticleIdList": ["10.1021/jf8028539", "19364111"]}, {"Citation": "Dinda B, Dinda S, DasSharma S, Banik R, Chakraborty A, Dinda M. Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders. Eur J Med Chem. 2017;131:68\u201380. doi:10.1016/j.ejmech.2017.03.004", "ArticleIdList": ["10.1016/j.ejmech.2017.03.004", "28288320"]}, {"Citation": "Zhao L, Wei Y, Huang Y, He B, Zhou Y, Fu J. Nanoemulsion improves the oral bioavailability of baicalin in rats: in vitro and in vivo evaluation. Int J Nanomedicine. 2013;8:3769\u20133779. doi:10.2147/IJN.S51578", "ArticleIdList": ["10.2147/IJN.S51578", "PMC3794992", "24124365"]}, {"Citation": "Shi F, Wei Z, Zhao Y, Xu X. Nanostructured lipid carriers loaded with baicalin: an efficient carrier for enhanced antidiabetic effects. Pharmacogn Mag. 2016;12(47):198. doi:10.4103/0973-1296.186347", "ArticleIdList": ["10.4103/0973-1296.186347", "PMC4989795", "27601850"]}, {"Citation": "Xiong F, Wang H, Cheng J, Zhu J. Determination of scutellarin in mouse plasma and different tissues by high-performance liquid chromatography. J Chromatogr B. 2006;835(1\u20132):114\u2013118. doi:10.1016/j.jchromb.2006.02.041", "ArticleIdList": ["10.1016/j.jchromb.2006.02.041", "16600699"]}, {"Citation": "Zheng C, Ou W, Shen H, Zhou Z, Wang J. Combined therapy of diabetic peripheral neuropathy with breviscapine and mecobalamin: a systematic review and a meta-analysis of Chinese studies. Biomed Res Int. 2015;2015. doi:10.1155/2015/680756", "ArticleIdList": ["10.1155/2015/680756", "PMC4383387", "25866802"]}, {"Citation": "Zheng C, Ou W, Shen H, Zhou Z, Wang J. Combined therapy of diabetic peripheral neuropathy with breviscapine and mecobalamin: a systematic review and a meta-analysis of Chinese studies. Biomed Res Int. 2015;2015:680756. doi:10.1155/2015/680756", "ArticleIdList": ["10.1155/2015/680756", "PMC4383387", "25866802"]}, {"Citation": "Wang J, Tan J, Luo J, et al. Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy. J Nanobiotechnology. 2017;15(1):18. doi:10.1186/s12951-017-0305-2", "ArticleIdList": ["10.1186/s12951-017-0305-2", "PMC5333415", "28249594"]}, {"Citation": "Matos M, Guti\u00e9rrez G, Coca J, Pazos C. Preparation of water-in-oil-in-water (W1/O/W2) double emulsions containing trans-resveratrol. Colloids Surf A Physicochem Eng Asp. 2014;442:69\u201379. doi:10.1016/j.colsurfa.2013.05.065", "ArticleIdList": ["10.1016/j.colsurfa.2013.05.065"]}, {"Citation": "Summerlin N, Soo E, Thakur S, Qu Z, Jambhrunkar S, Popat A. Resveratrol nanoformulations: challenges and opportunities. Int J Pharm. 2015;479(2):282\u2013290. doi:10.1016/j.ijpharm.2015.01.003", "ArticleIdList": ["10.1016/j.ijpharm.2015.01.003", "25572692"]}, {"Citation": "Bremer AA. Resveratrol use in metabolic syndrome. Metab Syndr Relat Disord. 2014;12(10):493\u2013495. doi:10.1089/met.2014.1505", "ArticleIdList": ["10.1089/met.2014.1505", "PMC4251086", "25229675"]}, {"Citation": "Bhakkiyalakshmi E, Sireesh D, Rajaguru P, Paulmurugan R, Ramkumar KM. The emerging role of redox-sensitive Nrf2-Keap1 pathway in diabetes. Pharmacological Res. 2015;91:104\u2013114. doi:10.1016/j.phrs.2014.10.004", "ArticleIdList": ["10.1016/j.phrs.2014.10.004", "25447793"]}, {"Citation": "Juhasz B, Mukherjee S, Das DK. Hormetic response of resveratrol against cardioprotection. Exp Clin Cardiol. 2010;15(4):e134.", "ArticleIdList": ["PMC3016073", "21264071"]}, {"Citation": "Juhasz B, Das DK, Kertesz A, Juhasz A, Gesztelyi R, Varga B. Reduction of blood cholesterol and ischemic injury in the hypercholesteromic rabbits with modified resveratrol, longevinex.[corrected]. Mol Cell Biochem. 2011;348(1\u20132):199\u2013203. doi:10.1007/s11010-010-0615-2", "ArticleIdList": ["10.1007/s11010-010-0615-2", "21052791"]}, {"Citation": "Juhasz B, Varga B, Gesztelyi R, Kemeny-Beke A, Zsuga J, Tosaki A. Resveratrol: a multifunctional cytoprotective molecule. Curr Pharm Biotechnol. 2010;11(8):810\u2013818.", "ArticleIdList": ["20874691"]}, {"Citation": "Mendez-del Villar M, Gonzalez-Ortiz M, Martinez-Abundis E, Perez-Rubio KG, Lizarraga-Valdez R. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2014;12(10):497\u2013501. doi:10.1089/met.2014.0082", "ArticleIdList": ["10.1089/met.2014.0082", "25137036"]}, {"Citation": "Hausenblas HA, Schoulda JA, Smoliga JM. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus\u2013systematic review and meta-analysis. Mol Nutr Food Res. 2015;59(1):147\u2013159. doi:10.1002/mnfr.201400173", "ArticleIdList": ["10.1002/mnfr.201400173", "25138371"]}, {"Citation": "Yu W, Fu YC, Wang W. Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem. 2012;113(3):752\u2013759. doi:10.1002/jcb.23431", "ArticleIdList": ["10.1002/jcb.23431", "22065601"]}, {"Citation": "Y\u00fccel \u00c7, Karatoprak G\u015e, Akta\u015f Y. Nanoliposomal resveratrol as a novel approach to treatment of diabetes mellitus. J Nanosci Nanotechnol. 2018;18(6):3856\u20133864. doi:10.1166/jnn.2018.15247", "ArticleIdList": ["10.1166/jnn.2018.15247", "29442719"]}, {"Citation": "Shahraki A, Bahadorikhalili S, Hashemzaei M, et al. Resveratrol nano-capsule as an efficient tool for blood pressure regulation: a study on metabolic syndrome induced mice. Biosci Biotechnol Res Commun. 2017;10(4):623\u2013630. doi:10.21786/bbrc/10.4/4", "ArticleIdList": ["10.21786/bbrc/10.4/4"]}, {"Citation": "Hoh CS, Boocock DJ, Marczylo TH, et al. Quantitation of silibinin, a putative cancer chemopreventive agent derived from milk thistle (Silybum marianum), in human plasma by high-performance liquid chromatography and identification of possible metabolites. J Agric Food Chem. 2007;55(7):2532\u20132535. doi:10.1021/jf063156c", "ArticleIdList": ["10.1021/jf063156c", "17355141"]}, {"Citation": "Tajmohammadi A, Razavi BM, Hosseinzadeh H. Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: a review. Phytother Res. 2018;32(10):1933\u20131949. doi:10.1002/ptr.6153", "ArticleIdList": ["10.1002/ptr.6153", "30015401"]}, {"Citation": "Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035\u20132063. doi:10.2165/00003495-200161140-00003", "ArticleIdList": ["10.2165/00003495-200161140-00003", "11735632"]}, {"Citation": "Huseini HF, Larijani B, Heshmat R, et al. The efficacy of silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res. 2006;20(12):1036\u20131039. doi:10.1002/ptr.1988", "ArticleIdList": ["10.1002/ptr.1988", "17072885"]}, {"Citation": "Das S, Roy P, Pal R, Auddy RG, Chakraborti AS, Mukherjee A. Engineered silybin nanoparticles educe efficient control in experimental diabetes. PLoS One. 2014;9(7):e101818. doi:10.1371/journal.pone.0101818", "ArticleIdList": ["10.1371/journal.pone.0101818", "PMC4081790", "24991800"]}, {"Citation": "Pereira M, Siba IP, Chioca LR, et al. Myricitrin, a nitric oxide and protein kinase C inhibitor, exerts antipsychotic-like effects in animal models. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1636\u20131644. doi:10.1016/j.pnpbp.2011.06.002", "ArticleIdList": ["10.1016/j.pnpbp.2011.06.002", "21689712"]}, {"Citation": "Sun GB, Qin M, Ye JX, et al. Inhibitory effects of myricitrin on oxidative stress-induced endothelial damage and early atherosclerosis in ApoE-/- mice. Toxicol Appl Pharmacol. 2013;271(1):114\u2013126. doi:10.1016/j.taap.2013.04.015", "ArticleIdList": ["10.1016/j.taap.2013.04.015", "23639522"]}, {"Citation": "Fernandez SP, Nguyen M, Yow TT, et al. The flavonoid glycosides, myricitrin, gossypin and naringin exert anxiolytic action in mice. Neurochem Res. 2009;34(10):1867\u20131875. doi:10.1007/s11064-009-9969-9", "ArticleIdList": ["10.1007/s11064-009-9969-9", "19387830"]}, {"Citation": "Ahangarpour A, Oroojan AA, Khorsandi L, Kouchak M, Badavi M. Solid lipid nanoparticles of myricitrin have antioxidant and antidiabetic effects on streptozotocin-nicotinamide-induced diabetic model and myotube cell of male mouse. Oxid Med Cell Longev. 2018;2018. doi:10.1155/2018/7496936", "ArticleIdList": ["10.1155/2018/7496936", "PMC6079346", "30116491"]}, {"Citation": "Goyal SK, Samsher GRK, Goyal RK. Stevia (Stevia rebaudiana) a bio-sweetener: a review. Int J Food Sci Nutr. 2010;61(1):1\u201310. doi:10.3109/09637480903193049", "ArticleIdList": ["10.3109/09637480903193049", "19961353"]}, {"Citation": "Kujur RS, Singh V, Ram M, et al. Antidiabetic activity and phytochemical screening of crude extract of stevia rebaudiana in alloxan-induced diabetic rats. Pharmacognosy Res. 2010;2(4):258\u2013263. doi:10.4103/0974-8490.69128", "ArticleIdList": ["10.4103/0974-8490.69128", "PMC3141138", "21808578"]}, {"Citation": "Barwal I, Sood A, Sharma M, Singh B, Yadav SC. Development of stevioside pluronic-F-68 copolymer based PLA-nanoparticles as an antidiabetic nanomedicine. Colloids Surf B. 2013;101:510\u2013516. doi:10.1016/j.colsurfb.2012.07.005", "ArticleIdList": ["10.1016/j.colsurfb.2012.07.005", "23022553"]}, {"Citation": "Fang EF, Ng TB. Chapter 28 - bitter gourd (momordica charantia) oils In: Preedy VR, editor. Essential Oils in Food Preservation, Flavor and Safety. San Diego: Academic Press; 2016:253\u2013257."}, {"Citation": "Paul D, Dey TK, Mukherjee S, Ghosh M, Dhar P. Comparative prophylactic effects of \u03b1-eleostearic acid rich nano and conventional emulsions in induced diabetic rats. J Food Sci Technol. 2014;51(9):1724\u20131736. doi:10.1007/s13197-014-1257-2", "ArticleIdList": ["10.1007/s13197-014-1257-2", "PMC4152491", "25190828"]}, {"Citation": "Balarini CM, Braga VA. New translational insights on metabolic syndrome: obesity, hypertension, diabetes and beyond. Front Physiol. 2016;7:229. doi:10.3389/fphys.2016.00229", "ArticleIdList": ["10.3389/fphys.2016.00229", "PMC4901063", "27375501"]}, {"Citation": "Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1\u20132):1\u201320.", "ArticleIdList": ["11166403"]}]}], "History": [{"Year": "2019", "Month": "4", "Day": "30"}, {"Year": "2019", "Month": "6", "Day": "25"}, {"Year": "2019", "Month": "8", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "8", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "10", "Day": "19", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "7", "Day": "16"}], "PublicationStatus": "epublish", "ArticleIdList": ["31406461", "PMC6642644", "10.2147/IJN.S213831", "213831"]}}]}